Clinical Trials Search | Clareo Health

Showing 1-1 of 1 trials

Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease

NCT06462469

The purpose of this study is to assess the efficacy and safety of ruxolitinib therapy in Chinese adults and adolescents (≥ 12 years old) with Grade II-IV steroid-refractory acute graft versus host disease (SR-aGvHD).

Steroid-refractory Acute Graft Versus Host Disease

Novartis Pharmaceuticals36 participantsStarted Jul 2024

Guangzhou, Guangdong, China • Guangzhou, Guangdong, China • Zhengzhou, Henan, China +14 more locations

Data from ClinicalTrials.govTerms

Filters

Filters

Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease

Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease